New imaging trick could spot HER2 cancers faster
NCT ID NCT07009184
First seen Nov 18, 2025 · Last updated May 19, 2026 · Updated 21 times
Summary
This early-phase study tests a new imaging agent called TGW211 for people with HER2-positive solid tumors. The goal is to see if a special "trigger" can help clear the imaging tracer from healthy organs quickly, making tumors easier to see on scans. About 19 adults will take part to check safety and how well the method works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Radboud University Medical Center
RECRUITINGNijmegen, Gelderland, 6525 GS, Netherlands
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.